Phaseline

Targets › TBXT

TBXT (T-box transcription factor T): drug programs, companies and trials

2 programs from 1 company in 3 trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Jul 2027.

Involved in the transcriptional regulation of genes required for mesoderm formation and differentiation. Binds to a palindromic T site 5'-TTCACACCTAGGTGTGAA-3' DNA sequence and activates gene transcription when bound to such a site. (UniProt, O15178)

Open in Phaseline: the race on TBXT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5
Therapeutic cancer vaccine expressing CEA, MUC1, and Brachyury tumor-associated antigens
CEA, MUC1, TBXTPhase 2Colorectal CarcinomaJul 2027
National Cancer Institute (NCI)Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform
Adenoviral-based cancer vaccine targeting CEA, Brachyury and MUC1
CEA, BRACHYURY, MUC1, KLK3, TBXTPhase 2Adenocarcinoma; Metastatic Colorectal CancerOct 2027

Conditions

Adenocarcinoma (1) Metastatic Colorectal Cancer (1) Colorectal Carcinoma (1)

Modalities

mixed (2)

Companies

National Cancer Institute (NCI) (2)

Related targets

CEA (2) MUC1 (2) BRACHYURY (1) KLK3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.